Key Points
- Natera CEO Steven Leonard Chapman sold 41,124 shares on June 4 at an average price of $221.03, totaling about $9.09 million. After the sale, he still held 108,743 shares, and the transaction was made under a pre-arranged Rule 10b5-1 plan.
- The stock was noted as down 3.1%, opening at $215.31, with a 52-week range of $131.81 to $256.36. Natera’s market cap was about $30.83 billion.
- Wall Street remains mostly positive on Natera, with a Moderate Buy consensus and a target price of $256.12. Recent analyst moves included higher price targets from JPMorgan and Piper Sandler, though one firm maintained a sell rating.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the transaction, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Steven Leonard Chapman also recently made the following trade(s):
- On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $185,956.32.
- On Monday, April 27th, Steven Leonard Chapman sold 5,838 shares of Natera stock. The stock was sold at an average price of $204.14, for a total value of $1,191,769.32.
- On Tuesday, March 10th, Steven Leonard Chapman sold 5,623 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $1,147,822.99.
Natera Stock Down 3.1%
NTRA stock opened at $215.31 on Friday. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The company has a market cap of $30.83 billion, a PE ratio of -132.09 and a beta of 1.56. The business's 50-day simple moving average is $204.19 and its 200 day simple moving average is $216.06.
Wall Street Analysts Forecast Growth
NTRA has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their target price on Natera from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Friday, May 8th. William Blair started coverage on Natera in a research note on Tuesday, April 14th. They issued an "outperform" rating on the stock. Piper Sandler reiterated an "overweight" rating and issued a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. Wells Fargo & Company upped their price objective on Natera from $215.00 to $220.00 and gave the company an "equal weight" rating in a research note on Friday, May 8th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Natera in a research note on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $256.12.
Get Our Latest Report on NTRA
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of NTRA. Reflection Asset Management acquired a new position in shares of Natera in the 4th quarter worth approximately $29,000. Palladiem LLC acquired a new position in shares of Natera in the 4th quarter worth approximately $31,000. Horizon Investments LLC acquired a new position in shares of Natera in the 3rd quarter worth approximately $32,000. International Assets Investment Management LLC boosted its holdings in shares of Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company's stock worth $35,000 after acquiring an additional 97 shares in the last quarter. Finally, Bank of Jackson Hole Trust boosted its holdings in shares of Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock worth $37,000 after acquiring an additional 83 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.
Natera Company Profile
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
